Form 4: Tourmaline Bio Director Mark McDade Granted 16,800 Stock Options

Tourmaline Bio, Inc. director Mark McDade was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.

Summary

• Mark McDade, a Director of Tourmaline Bio, Inc. (TRML), was the reporting person for this transaction.
• On June 4, 2025, Mr. McDade acquired 16,800 stock options.
• Each stock option has an exercise price of $18.73.
• The options are for the right to buy 16,800 shares of Tourmaline Bio Common Stock.
• The options will vest 100% on the earlier of the anniversary of the transaction date (June 4, 2026) or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Mr. McDade's continued service.
• The stock options have an expiration date of June 4, 2035.
• Following this transaction, Mr. McDade beneficially owns 16,800 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine insider equity grant, which is a positive for aligning management incentives with shareholder interests, indicating stability in governance and compensation practices.

Positives

• The grant of stock options to Director Mark McDade aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.

Future Outlook

The grant of long-term stock options to Director Mark McDade suggests an expectation of his continued service and aligns his future incentives with the company's long-term performance and shareholder value creation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key leadership, aligning their financial interests with the long-term success and growth of the company.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value creation, as the options' value is tied to the company's stock performance.
• Employees: Standard and competitive compensation practices, including equity grants, can positively influence overall employee morale and retention within the company.

Next Steps

• Continued service of Mark McDade as a Director of Tourmaline Bio, Inc.
• Vesting of 16,800 stock options on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.
• Potential exercise of stock options by Mark McDade prior to their expiration on June 4, 2035.

Key Dates

Recommendation

Keywords

Tourmaline Bio, TRML, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership